---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-26-000039"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:50:50.521460+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcutis Q1 2026 revenue $105.4M (+65% YoY); net loss narrows to $11.3M

## Summary
- Net product revenue of $105.4M from ZORYVE, up 65% YoY but down 17% sequentially due to Q1 seasonality.
- Net loss of $11.3M ($0.09 per share) vs $25.1M loss in Q1 2025; positive operating cash flow of $2.2M.
- FY 2026 revenue guidance maintained at $480M–$495M; cash and equivalents $224.3M at quarter end.
- Submitted sNDA for ZORYVE cream 0.05% in atopic dermatitis for infants 3–24 months; initiated Phase 1 for ARQ-234.
- Completed dermatology sales force expansion; hired head of Primary Care Franchise to target pediatric providers.

## SEC filing metadata
- accession: 0001787306-26-000039
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730626000039/0001787306-26-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730626000039/arqt-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-26-000039
- JSON: https://secwatch.observer/filing/0001787306-26-000039.json
- Plain text: https://secwatch.observer/filing/0001787306-26-000039.txt

## Source-grounded claims
- claim_id: f590c04cebce77d277a11694d4bd2bee0bf1a898
  claim: Arcutis Biotherapeutics, Inc. reported the quarter ended March 31, 2026 results: revenue $105.4 million.
  evidence_excerpt: --- EX-99.1 (EX-99.1) --- Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update • Q1 2026 net product revenue for ZORYVE® (roflumilast) was $105.4 million, a 65% increase compared to Q1 2025, and a 17% decrease compared to Q4 2025 • Continued strong demand for ZORYVE despite typical Q1 seasonality, with continued growth in share of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730626000039/0001787306-26-000039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.